Alumis (ALMS) Receivables (2025)

Alumis (ALMS) posted quarterly Receivables of $1.4 million for Q4 2025, down 30.86% quarter-over-quarter from $2.1 million in Q3 2025.

Analysis

Alumis (ALMS) Receivables (2025) Analysis & Trends

Alumis (ALMS) has reported Receivables for 1 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
Receivables slipped to $1.4 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
Across five years, Receivables topped out at $5.0 million in Q2 2025 and bottomed at $1.4 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	160.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.06 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	912.74 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	215.33 Mn
10	Alumis	1.42 Bn	919.00 Mn	-	-

Historic Data

Download Data